Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

REGENERON PHARMACEUTICALS INC

Form 4

December 19, 2014

FORM	Ī							OMB AF	PPROVAL	
· Ortiv	UNITED ST	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								
Check th if no long subject to Section 1 Form 4 o Form 5 obligatio may cont See Instru 1(b).	STATEME 6. 6. r Filed pursu sinue. Section 17(a)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							January 31, 2005 average rs per 0.5	
(Print or Type I	Responses)									
1. Name and A Van Plew D	address of Reporting Per Paniel P	Symbol REGEN PHARN	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last)	(First) (Mic		3. Date of Earliest Transaction				X_ Officer (give below)			
777 OLD SA	AW MILL RIVER		(Month/Day/Year) 12/18/2014				SVP & General Mgr Industrial O			
	nendment, Date Original onth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting					
TARRYTO	WN, NY 10591						Person	iore man One Re	porting	
(City)	(State) (Zi	ip) Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	8	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	(Instr. 3,	spose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	12/18/2014		M	3,264	A	\$ 30.63	18,705	D		
Common Stock							1,394	I	By 401(k) Plan	
Reminder: Rep	oort on a separate line fo	or each class of secu	rities benefi	icially owr	ned din	rectly or i	ndirectly.			

Persons who respond to the collection of

information contained in this form are not

required to respond unless the form displays a currently valid OMB control

number.

1

SEC 1474

(9-02)

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)	\$ 30.63	12/18/2014		M	3,264	<u>(1)</u>	12/14/2020	Common Stock	3,264

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Van Plew Daniel P 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591

SVP & General Mgr Industrial O

Signatures

/s/**Daniel P. Van Plew 12/19/2014

**Signature of Reporting Date
Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2